Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DSU7K2
|
|||
Drug Name |
Tosyl-l-arginine methyl ester
|
|||
Synonyms |
Tame; 901-47-3; Methyl P-toluenesulfonyl-L-argininate; Ts-Arg-OMe; tosyl-arginine methyl ester; UNII-1H7BKF44U1; p-toluenesulfonyl-L-arginine methyl ester; tosyl-L-arginine methyl ester; CHEMBL44752; methyl (2S)-5-(diaminomethylideneamino)-2-[(4-methylphenyl)sulfonylamino]pentanoate; 1H7BKF44U1; CHEBI:62167; methyl N(2)-(p-tosyl)-L-argininate; p-toluensulfonyl-L-arginine methyl ester; N(alpha)-p-tosyl-L-arginine methyl ester; (S)-methyl 5-guanidino-2-(4-methylphenylsulfonamido)pentanoate; methyl N(2)-(p-toluenenesulfonyl)-L-argininate; methyl N(2)-[(p-tolyl)sulphonyl]-L-argininate; N(2)-(p-tolylsulfonyl)-L-arginine methyl ester; methyl N(2)-[(4-methylphenyl)sulfonyl]-L-argininate; L-Arginine, N2-((4-methylphenyl)sulfonyl)-, methyl ester; TOSYLARGININE METHYL ESTER; TAME/; SCHEMBL324561; p-tosyl-l-arginine methyl ester; Nalpha-tosylarginine methyl ester; BCPP000052; ZINC1639578; ABP000326; BDBM50070707; s2225; AKOS030214485; CCG-264948; CS-0466; alpha-N-p-Tosyl-L-arginine methyl ester; NCGC00346615-01; HY-13255; SW219688-1; X7573; N-alpha-Toluenesulfonyl-L-arginine methyl ester; W-5260; AB01566842_01; p-TOLUENESULFONYL-L-ARGININE METHYL ESTER HCl; Q27131658; (S)-5-Guanidino-2-(toluene-4-sulfonylamino)-pentanoic acid methyl ester
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Preclinical | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C14H22N4O4S
|
|||
Canonical SMILES |
CC1=CC=C(C=C1)S(=O)(=O)NC(CCCN=C(N)N)C(=O)OC
|
|||
InChI |
1S/C14H22N4O4S/c1-10-5-7-11(8-6-10)23(20,21)18-12(13(19)22-2)4-3-9-17-14(15)16/h5-8,12,18H,3-4,9H2,1-2H3,(H4,15,16,17)/t12-/m0/s1
|
|||
InChIKey |
FKMJXALNHKIDOD-LBPRGKRZSA-N
|
|||
CAS Number |
CAS 901-47-3
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:62167
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cell division cycle protein 20 homolog (CDC20) | Target Info | Inhibitor | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12. | |||
REF 2 | Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015 Jul;151:141-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.